An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)

Evaluation of Safety and Efficacy of Xeloda in Metastatic Colorectal Carcinoma

This prospective observational study will evaluate the safety and efficacy of Xeloda (capecitabine) administered in monotherapy in patients with metastatic colorectal cancer. Patients will be followed until disease progression or unacceptable toxicity occurs.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Metastatic colorectal cancer
• Receiving Xeloda according to registered indication

Exclusion Criteria:

• Patients who are not eligible for Xeloda treatment according to the Summary of Product Characteristics